InvestorsHub Logo
Followers 14
Posts 535
Boards Moderated 0
Alias Born 10/15/2012

Re: None

Friday, 08/08/2014 1:44:12 AM

Friday, August 08, 2014 1:44:12 AM

Post# of 2538
HEPLISAV-B phase 3 trial moving forward

DV1179 treatment for Lupus did not meet primary or secondary endpoints in phase 1b/2a trial.

AZD1419 meets primary and secondary endpoints in phase 1 trial to treat asthma.

I will continue to look for opportunities to add to my investment, as I feel that while other pipeline products add value to Dynavax, Heplisav-B will be the driver of pps over the next few years.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DVAX News